Kazuhito Yamamoto

20PUBLICATIONS
86CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsMedical biotechnology diagnostics (incl. biosensors)Biologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Aug 14, 2026
ELTS Score and Early "Warning" Define a Two-Stage Risk Framework for Failure-Free Survival in Chronic-Phase CML.

|Sep 02, 2025
Final results of JCOG0601 randomized trial of R-CHOP versus CHOP combined with dose-dense rituximab for diffuse large B-cell lymphoma.

Ken Ohmachi, Tomohiro Kinoshita, Dai Maruyama

|May 28, 2025
Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial.

Koji Izutsu, Takahiro Kumode, Junichiro Yuda

|Feb 08, 2025
Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 study.

Satoshi Iyama, SungGi Chi, Masashi Idogawa

|Sep 01, 2023
Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan.

Takashi Mizuoka, Hiroyuki Sakamaki, Shigeo Fuji

|May 26, 2023
Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406.

Michinori Ogura, Kazuhito Yamamoto, Yasuo Morishima

Pageof 4

Frequent Collaborators

5 joint publications

Dai Maruyama

4 joint publications

Takaaki Ono

4 joint publications

Naoto Takahashi

3 joint publications

Koji Izutsu